Subject: early-stage breast cancer

---

Year: 2019

---

Type: Article

---

Title: Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

---

Author: Delaloge, S
Author: Cella, D
Author: Ye, Y
Author: Buyse, M
Author: Chan, A
Author: Barrios, C H
Author: Holmes, F A
Author: Mansi, J
Author: Iwata, H
Author: Ejlertsen, B
Author: Moy, B
Author: Chia, S K L
Author: Gnant, M
Author: Smichkoska, Snezhana
Author: Ciceniene, A
Author: Martinez, N
Author: Filipović, S
Author: Ben-Baruch, N E
Author: Joy, A A
Author: Langkjer, S T
Author: Senecal, F
Author: de Boer, R H
Author: Moran, S
Author: Yao, B
Author: Bryce, R
Author: Auerbach, A
Author: Fallowfield, L
Author: Martin, M

---

Abstract: We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in human epidermal growth factor receptor-2-positive early-stage breast cancer.

---

Publisher: Elsevier BV

---

Relation: Annals of Oncology

---

Identifier: oai:repository.ukim.mk:20.500.12188/7219
Identifier: http://hdl.handle.net/20.500.12188/7219
Identifier: 10.1093/annonc/mdz016
Identifier: https://api.elsevier.com/content/article/PII:S0923753419311123?httpAccept=text/xml
Identifier: https://api.elsevier.com/content/article/PII:S0923753419311123?httpAccept=text/plain
Identifier: http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz016/28492154/mdz016.pdf
Identifier: http://academic.oup.com/annonc/article-pdf/30/4/567/28564988/mdz016.pdf
Identifier: 30
Identifier: 4
Identifier: 567
Identifier: 574

---